DuOtic Adds a Dog-Only Otic Option for Yeast-Associated Otitis Externa
DuOtic™ joins the veterinary otology toolbox as a prescription otic gel for dogs with otitis externa linked to susceptible strains of Malassezia pachydermatis. The label makes the intended use unusually explicit: this is for dogs only, and it should not be used in cats. Federal law restricts administration to a licensed veterinarian or a veterinarian’s order, which places the product firmly inside supervised clinical care rather than owner-directed ear treatment.
The formulation pairs terbinafine, an antifungal agent, with betamethasone acetate, a corticosteroid. That combination reflects a common clinical logic in inflamed ear canals: suppress the organism driving the infection while also damping the edema, erythema, and pruritus that keep the cycle going. In practical terms, fungal overgrowth and inflammation often feed each other inside the external ear canal, where moisture, debris, and self-trauma can sustain disease even after the initial trigger is addressed.
The Label Requires Careful Ear Selection Before Every Dose
The product is not a casual empiric ear drop. Before each administration, the tympanic membrane must be confirmed intact. Dogs with known tympanic perforation are excluded from use, and the label states plainly that use in perforated membranes has not been evaluated. The warning is clinically important because any otic medication that reaches the middle ear can raise the risk of vestibular and neurologic complications, especially when the barrier between the external and middle ear is compromised.
The recommended procedure starts with cleaning and drying the external ear canal before the first dose. After that, one tube is delivered per affected ear, then repeated seven days later. The gel is applied directly into the external ear canal, followed by gentle massage at the base of the ear to improve distribution into the lower canal. A notable instruction follows: do not clean the ear canal for 45 days after the initial administration, since cleansing may reduce contact time and weaken effectiveness. If another otic therapy becomes necessary, the ear should be cleaned before that alternative treatment is applied.
One sentence captures the operational reality: the product is designed to stay where the inflammation lives.
Ocular Exposure Is a Real Human Safety Issue
The label places heavy emphasis on human safety during administration. Eye protection is advised, and clinicians are told to restrain the dog to reduce head shaking and splatter after application. That precaution is not cosmetic. Accidental eye exposure can cause injury and irritation, and if exposure occurs the eyes should be flushed thoroughly with water for at least 15 minutes. Contact lens wearers are instructed to rinse first, remove lenses, and continue flushing. Skin contact should be washed off promptly, and accidental ingestion by humans warrants physician consultation.
The concern around splatter is grounded in the mechanics of otic delivery. A dog that shakes its head immediately after instillation can propel product outward, creating a direct pathway to the clinician’s face and eyes and to nearby handlers. The label also instructs against oral administration, reinforcing that this is a localized otic product, not a systemic therapy.
Middle Ear Effects and Corticosteroid Caution Shape the Risk Profile
Several precautions tie directly to the pharmacology of the product. Topical otic corticosteroids have been associated with adrenocortical suppression and iatrogenic hyperadrenocorticism in dogs, so the steroid component is not biologically neutral simply because it is delivered into the ear canal. The label also advises caution in dogs with impaired hepatic function, which is consistent with the need for careful monitoring when drug disposition may be altered.
The safety section also points to adverse middle ear findings that have been associated with Osurnia®, a related product containing the same concentrations of terbinafine and betamethasone acetate. Those findings include ulceration of the mucosal lining in the middle ear and reported signs such as tympanic membrane rupture, head tilt, ataxia, nystagmus, facial paralysis, and keratoconjunctivitis sicca. The presence of these warnings does not mean every dog is at risk, but it does mean the ear should be examined with precision before treatment and re-evaluated promptly if hearing loss or vestibular signs emerge during therapy.
Field Data Show Low-Frequency Adverse Events but Signal the Need for Monitoring
A US field study included 120 dogs treated with DuOtic and 119 dogs in the control group. Reported adverse reactions were uncommon, but they were not absent. Four dogs in the DuOtic arm had elevated alanine aminotransferase at study exit, a finding that resolved on later chemistry testing in three dogs; no follow-up was available for the fourth dog. Elevated alanine aminotransferase occurred in 3.3% of treated dogs and in none of the controls. Conjunctivitis appeared in 0.8% of treated dogs, while ocular discharge was reported in 0.8% of treated dogs and 1.7% of controls. Ear discharge and ear pruritus were also recorded, with ear pruritus reported in both groups.
These numbers do not suggest a broad toxicity signal, but they do support a familiar veterinary principle: localized otic therapy still deserves systemic vigilance when corticosteroids and antifungal agents are combined. Liver enzyme changes, ocular irritation, and ear discomfort are exactly the kinds of events that can be missed if follow-up is limited to symptom resolution alone.
Post-Approval Reports Expand the Safety Conversation Beyond the Trial
Post-approval experience with Osurnia® is especially relevant because DuOtic contains identical concentrations of terbinafine and betamethasone acetate. Reported adverse events in dogs include deafness, ear discharge, pinnal irritation, ear pain, emesis, head shaking, internal ear disorder with head tilt and vestibular signs, ataxia, vocalization, corneal ulcer, keratoconjunctivitis sicca, nystagmus, tympanic rupture, and cranial nerve disorder with facial paralysis. In humans, accidental ocular exposure after a dog shook its head following application was linked to corneal ulcers and other eye injuries, along with irritation, burning, stinging, and itchiness.
Extra-label use in cats is specifically cautioned against by the label’s safety history, where adverse events included ataxia, anorexia, Horner’s syndrome, internal ear disorder, anisocoria, lethargy, head shaking, emesis, nystagmus, deafness, and tympanic rupture. The cat warning is not a side note; it is a direct signal that species boundaries matter here.
Practical Use Depends on Exam Discipline, Not Just the Tube Count
For clinicians, the major clinical message is straightforward. DuOtic offers a targeted option for canine otitis externa associated with susceptible Malassezia pachydermatis, but the label demands a thorough ear examination, confirmation of tympanic integrity, and careful handling during administration. Dogs with vestibular or hearing changes during treatment need reassessment, and dogs with hepatic impairment deserve extra caution.
The product’s design also makes patient handling part of the therapeutic plan. Restraint, eye protection, and attention to head shaking are not peripheral precautions; they are part of safe delivery. The label’s strongest limitation is also its clearest boundary: this therapy is confined to dogs with intact tympanic membranes, and the safety margin narrows quickly when that anatomic barrier is uncertain.